Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06824987 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
MinorEnrollment closed, study ongoingPrimary and study completion pushed from Aug 30, 2027 to Oct 4, 2027 · Trial sites reduced: 96 → 63 locations · Trial sites expanded: 89 → 96 locations · 1 moreShow 4 more changesShow less
Primary and study completion pushed from Aug 30, 2027 to Oct 4, 2027
Trial sites reduced: 96 → 63 locations
Trial sites expanded: 89 → 96 locations
Final enrollment: 57 participants (planned 136)
MinorTrial status: Recruiting to Active, Not RecruitingEnrollment target: estimated 136 to confirmed 57 · Study sites: 89 to 96 · Primary and study completion dates: Aug 30, 2027 to Oct 4, 2027 · 2 moreShow 5 more changesShow less
Enrollment target: estimated 136 to confirmed 57
Study sites: 89 to 96
Primary and study completion dates: Aug 30, 2027 to Oct 4, 2027
Eligibility criteria expanded, about 23 words
Secondary endpoints: details revised at 1 of 9 entries
MinorEnrollment target: 96 to 136Study sites: 77 to 89 · Eligibility criteria expanded, about 70 words · Secondary endpoints revised (9) · 2 morev9Show 5 more changesShow less
NotableTrial status: Not Yet Recruiting to RecruitingStudy sites: 20 to 32 · Primary and study completion dates: Sep 2, 2027 to Aug 30, 2027 · Start date changed from estimate of Mar 10, 2025 to Mar 5, 2025v3Show 3 more changesShow less
Study sites: 20 to 32
Primary and study completion dates: Sep 2, 2027 to Aug 30, 2027
Start date changed from estimate of Mar 10, 2025 to Mar 5, 2025
NotableLead sponsor: [Redacted] to AstraZenecaTrial status: Withheld to Not Yet Recruiting · Primary and study completion dates: Sep 2, 2027 · Start date: Mar 10, 2025 · 1 morev2Show 4 more changesShow less
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to assess the efficacy and safety of AZD2373 in participants diagnosed with APOL1-Mediated Kidney Disease (AMKD) who are homozygotes or compound heterozygotes for APOL1 high-risk genotypes (G1 and G2). The primary hypothesis to be evaluated is that AZD2373, compared with placebo, will result in a greater reduction in UACR as assessed by the relative change from Baseline in UACR at Week 30.